Dianthus Therapeutics Forecast, price target & analysts
Dianthus Therapeutics Target price 2026 - Analyst rating & recommendation
Dianthus Therapeutics Classifications & Recommendation
Dianthus Therapeutics Price Target
| Target Price | $135.15 |
| Price | $96.81 |
| Potential |
39.60%
register free of charge
|
| Number of Estimates | 16 |
|
16 Analysts have issued a price target Dianthus Therapeutics 2027 .
The average Dianthus Therapeutics target price is $135.15.
This is
39.60%
register free of charge
$210.00
116.92%
register free of charge
$123.22
27.28%
register free of charge
|
|
| A rating was issued by 22 analysts: 21 Analysts recommend Dianthus Therapeutics to buy, 1 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Dianthus Therapeutics stock has an average upside potential 2027 of
39.60%
register free of charge
|
Sales and Margin forecast 2026, 2027 to 2033
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Revenue Million $ | 2.04 | 1.86 |
| 67.31% | 8.82% | |
| Net Margin | -7,957.84% | -11,469.83% |
| 484.41% | 44.13% |
15 Analysts have issued a sales forecast Dianthus Therapeutics 2026 . The average Dianthus Therapeutics sales estimate is
This results in the following potential growth metrics:
16 Dianthus Therapeutics Analysts have issued a net profit forecast 2026. The average Dianthus Therapeutics net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2026, 2027 to 2033
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -4.20 | -3.89 |
| 64.71% | 7.38% | |
| P/E | negative | |
| EV/Sales | 2,434.52 |
16 Analysts have issued a Dianthus Therapeutics forecast for earnings per share. The average Dianthus Therapeutics EPS is
This results in the following potential growth metrics and future valuations:
Dianthus Therapeutics...
Current Dianthus Therapeutics Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| JP Morgan |
Locked
➜
Locked
|
Locked | Sep 11 2026 |
| Citigroup |
Locked
➜
Locked
|
Locked | Sep 04 2026 |
| Truist Securities |
Locked
➜
Locked
|
Locked | Aug 06 2026 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Aug 06 2026 |
| Wedbush |
Locked
➜
Locked
|
Locked | Aug 05 2026 |
| Evercore ISI Group |
Locked
➜
Locked
|
Locked | Aug 03 2026 |
| Wedbush |
Locked
➜
Locked
|
Locked | May 06 2026 |
| Analyst Rating | Date |
|---|---|
|
Locked
JP Morgan:
Locked
➜
Locked
|
Sep 11 2026 |
|
Locked
Citigroup:
Locked
➜
Locked
|
Sep 04 2026 |
|
Locked
Truist Securities:
Locked
➜
Locked
|
Aug 06 2026 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Aug 06 2026 |
|
Locked
Wedbush:
Locked
➜
Locked
|
Aug 05 2026 |
|
Locked
Evercore ISI Group:
Locked
➜
Locked
|
Aug 03 2026 |
|
Locked
Wedbush:
Locked
➜
Locked
|
May 06 2026 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
